The MEA liquid biopsy market size surpassed USD 1.09 billion in 2025 and is predicted to reach around USD 2.88 billion by 2035, registering a CAGR of 10.2% from 2026 to 2035. There is a growing preference for non-invasive diagnostics, precision medicine, personalized treatment plans, and increased government investment in healthcare infrastructure across the Middle East.

MEA Liquid Biopsy Market Statical Scope

Countries like the UAE have introduced a new program to support early diagnosis of non-small cell lung cancer , which accounts for around 80-85% of lung cancer cases globally. Companies like Johnson & Johnson have implied that the liquid biopsy test has immense potential to analyze up to 74 cancer-linked genes, with results within 7 days.

The UAE has expanded access to advanced testing for lung cancer patients. Moreover, Abu Dhabi is also setting a benchmark in healthcare by introducing tests to detect more than 50 cancer types. The Multi-Cancer Early Detection (MCED) blood test was launched by the Department of Health (DoH) and the Abu Dhabi Public Health Center.

MEA Liquid Biopsy Market Share, By Sample Type, 2025 (%)

• Blood Sample - The blood sample segment dominated the market in 2025 with a share of 95%, owing to the minimally invasive nature and the ease of collection of blood samples. Blood samples are widely preferred for early cancer detection and treatment monitoring. They have wide applications in precision medicine across healthcare settings.
• Others - The others segment held a share of 5% and is expected to grow in the coming years, driven by alternative sample types such as urine, saliva, and cerebrospinal fluid. These samples are used for specialized diagnostic applications.

MEA Liquid Biopsy Market Share, By Biomarker, 2025 (%)

• Circulating Nucleic Acids - The circulating nucleic acids segment dominated the market in 2025 with a share of 42%, supported by the increasing use of circulating tumor DNA and RNA analysis for non-invasive cancer diagnostics, disease monitoring, and therapy selection. Among these, cell-free DNA and circulating tumor DNA are the most crucial segments of the liquid biopsy industry.
• Circulating Tumor Cells (CTCs) - The circulating tumor cells segment held a 27% share and is expected to grow in the coming years due to the growing adoption in cancer prognosis and metastatic disease assessment. Circulating tumor cells are of great importance in oncological research.

MEA Liquid Biopsy Market Share, By Technology, 2025 (%)

• Multi-gene parallel Analysis (NGS) - The multi-gene parallel analysis segment dominated the market in 2025 with a share of 58%, owing to its high sensitivity and ability to analyze multiple genetic mutations simultaneously. It is increasingly adopted in precision oncology and companion diagnostics.
• Single Gene Analysis (PCR Microarrays) - The single gene analysis segment held a 42% share and is expected to grow in the coming years, driven by its cost-effectiveness, rapid turnaround time, and continued use in targeted mutation analysis. Single-gene tests enable rapid therapeutic decisions for targeted therapy.

MEA Liquid Biopsy Market Share, By Application, 2025 (%)

• Cancer - The cancer segment dominated the market in 2025 with a share of 84%, led by the rising prevalence of cancer and the increasing demand for non-invasive diagnostic techniques. Liquid biopsy is supported by the rising adoption of personalized treatment strategies.
• Reproductive Health - The reproductive health segment held a 16% share and is expected to grow in the coming years, driven by the expanding use of liquid biopsy technologies in prenatal testing and reproductive disorder screening. Liquid biopsy has wide applications in endometrial health and recurrent pregnancy loss.

MEA Liquid Biopsy Market Share, By End Use, 2025 (%)

• Hospitals and Laboratories - The hospitals and laboratories segment dominated the market in 2025 with a share of 49%, owing to high patient volumes and advanced diagnostic infrastructure. They are leading due to the increasing integration of liquid biopsy testing into routine oncology care.
• Specialty Clinics - The specialty clinics segment held a 23% and is expected to grow in the coming years, driven by the growing availability of precision medicine and specialized cancer diagnostic services. Liquid biopsy used in specialty clinics plays a vital role in early detection and screening, real-time monitoring, and treatment selection.

MEA Liquid Biopsy Market Share, By Clinical Application, 2025 (%)

• Therapy Selection - The therapy selection segment dominated the market in 2025 with a share of 28%, owing to the increasing use of liquid biopsy testing to identify actionable genetic mutations and guide personalized treatment decisions. The major roles of liquid biopsy in therapy selection include initial molecular profiling, real-time treatment monitoring, and resistance detection.
• Treatment Monitoring - The treatment monitoring segment held a 25% share and is expected to grow in the coming years, driven by the rising adoption of real-time diseas tracking and assessment of therapeutic effectiveness. Liquid biopsy also plays a critical role in guiding therapy adjustments and providing a non-invasive treatment approach

MEA Liquid Biopsy Market Share, By Product, 2025 (%)

• Consumables Kits and Reagents - The consumables kits and reagents segment dominated the market in 2025 with a share of 56%, accelerated by their recurring usage in liquid biopsy procedures. They are also driven by increasing testing volumes across diagnostic laboratories.
• Instruments - The instruments segment held a 26% share and is expected to grow in the coming years, driven by the growing installation of advanced sequencing and analytical platforms in healthcare facilities. The widely used instruments include automated liquid handling systems, centrifuges, magnetic bead technology, filtration systems, and lab-on-a-chip devices

Competitive Landscape

The leading innovators in the liquid biopsy industry in North America are Guardant Health, Natera, Inc., Exact Sciences, F. Hoffmann-La Roche Ltd., Illumina, Inc., Bio-Rad Laboratories, Labcorp, Tempus AI, Inc., NeoGenomics Inc., and GRAIL, Inc. They have adopted multi-cancer early detection and AI-driven analysis for therapy selection and recurrence monitoring. The core offerings include integrated diagnostics, ultra-sensitive and personalized circulating tumor DNA (ctDNA) test for molecular residual disease assessment and recurrence monitoring, personalized medicine assays, and many more.

Segments Covered in the Report

By Sample Type

• Blood Sample
• Others

By Biomarker

• Circulating Nucleic Acids
• Circulating Tumor Cells (CTCs)
• Exosomes/Microvesicles
• Others

By Technology

• Multi-gene Parallel Analysis (NGS)
• Single Gene Analysis (PCR Microarrays)

By Application

• Cancer
• Reproductive Health

By End Use

• Hospitals and Laboratories
• Specialty Clinics
• Academic and Research Centers
• Others

By Clinical Application

• Therapy Selection
• Treatment Monitoring
• Early Cancer Screening
• Recurrence Monitoring
• Others

By Product

• Consumables Kits and Reagents
• Instruments
• Software and Services